Adjuvant Chemotherapy in Retinoblastoma with Postlaminar Optic Nerve Invasion: A Global Multicenter Study.
AI interpretation is pending for this paper.
Open original publication →What the AI sees
Not AI summarized yet.
Research significance
Pending deeper interpretation.
Source abstract
PURPOSE: To evaluate outcomes of patients with retinoblastoma (RB) who underwent primary enucleation with histopathologic evidence of postlaminar optic nerve invasion (PLONI), comparing those who received adjuvant chemotherapy to those who did not. DESIGN: Multicenter retrospective cohort study. PARTICIPANTS: A total of 292 patients across 9 countries with RB and histopathologic evidence of PLONI after primary enucleation. METHODS: Patients who received adjuvant chemotherapy (n = 276) were compared with those who did not (n = 16) using Fisher exact tests, Welch t tests, and proportional hazard models (Cox and competing risks). Subanalyses were performed for PLONI and massive choroidal invasion and isolated PLONI. MAIN OUTCOME MEASURES: Orbital tumor recurrence, metastasis, and death. RESULTS: Patients who did not receive adjuvant chemotherapy had higher rates of orbital tumor recurrence (31% vs 2%, P < 0.001), metastasis (31% vs 6%, P = 0.001), and death (38% vs 9%, P = 0.007). In time-to-event analyses, patients who did not receive adjuvant chemotherapy experienced greater hazard of orbital tumor recurrence (subhazard ratio [SHR] = 19.31, 95% confidence interval [CI]: 5.56-67.05), metastasis (SHR = 5.39, 95% CI: 1.75-16.60), and death (hazard ratio = 4.74, 95% CI: 1.75-12.81). Outcomes were similar among patients with PLONI and massive choroidal invasion. Among patients with isolated PLONI, those who did not receive adjuvant chemotherapy showed significantly greater hazard of metastasis over time than those who received adjuvant chemotherapy (SHR = 40.68, 95% CI: 9.65-171.55, P < 0.001). All patients with metastasis or orbital tumor recurrence eventually died during follow-up (mean duration: 75.3 months). CONCLUSIONS: In patients with RB and PLONI with additional high-risk histopathologic features, initiating adjuvant chemotherapy after primary enucleation significantly reduced rates of orbital tumor recurrence, metastasis, and death. Although patients with isolated PLONI experienced fewer events and had a lower metastatic risk compared with those with multiple histopathologic features, adjuvant chemotherapy still reduced metastatic risk over time. FINANCIAL DISCLOSURE(S): The authors have no proprietary or commercial interest in any materials discussed in this article.